Sign In
Buy ORGS
$0.590
+0.0950 (+19.19%)
At Close: Jun 03, 2026
Orgenesis Inc. Announces $2.3 Million Private Placement
08:30am, Monday, 04'th Mar 2024
GERMANTOWN, Md., March 04, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), announced tod
GERMANTOWN, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), today announced
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
09:15am, Wednesday, 31'st Jan 2024
GERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announce
Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM
08:30am, Tuesday, 14'th Nov 2023
GERMANTOWN, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene
Orgenesis Provides Business Update for the Third Quarter of 2023
04:15pm, Monday, 13'th Nov 2023
GERMANTOWN, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc.
Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering
09:00am, Wednesday, 08'th Nov 2023
GERMANTOWN, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (“Orgenesis”) (Nasdaq: ORGS), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), ann
Orgenesis Announces Withdrawal of Proposed Public Offering
09:30pm, Monday, 30'th Oct 2023
GERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene
Orgenesis Announces Proposed Underwritten Public Offering
04:07pm, Monday, 30'th Oct 2023
GERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene
Orgenesis Provides Business Update for Second Quarter of 2023
07:00am, Friday, 11'th Aug 2023
Reports Progress in Advancing the Rollout of the POCare Platform and POCare Therapeutic Pipeline Orgenesis to Host Conference Call Today at 8:00 AM ET GERMANTOWN, Md., Aug. 11, 2023 (GLOBE NEWSWIRE
Orgenesis Schedules Second Quarter 2023 Business Update Conference Call
08:30am, Thursday, 10'th Aug 2023
GERMANTOWN, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene
Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer
08:30am, Thursday, 13'th Jul 2023
GERMANTOWN, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene
Orgenesis to Participate in Benchmark's 3rd Annual Healthcare House Call Virtual 1x1 Investor Conference on May 23, 2023
08:30am, Friday, 19'th May 2023
GERMANTOWN, Md., May 19, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene t
Orgenesis Schedules Fourth Quarter 2022 Business Update Conference Call
09:00am, Friday, 17'th Mar 2023
GERMANTOWN, Md., March 17, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gen
New Dimensions Trading Discloses Large Position in ORGS / Orgenesis
12:27am, Wednesday, 23'rd Nov 2022
Fintel reports that New Dimensions Trading has filed a 13G form with the SEC disclosing ownership of 1,370,000 shares of Orgenesis Inc (ORGS).
Orgenesis (ORGS) Q3 2022 Earnings Call Transcript
09:29pm, Sunday, 13'th Nov 2022
Orgenesis (NASDAQ:ORGS ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants David Waldman - Investor Relations Vered Caplan - Chief Executive Officer Neil Reithinger -
